Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting

This article was originally published in The Pink Sheet Daily

Executive Summary

Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.

You may also be interested in...

Keryx Aims For Ironclad Hold On Hyperphosphatemia Market

Recently-approved (and still un-trade named) phosphate binder ferric citrate could unseat the market leader due to its unique ability to increase iron in patients, firm believes, although it didn’t get the full set of labeling claims it sought.

First Quarter Earnings Dampened By Severe Weather

Keryx cautions investors that a Zerenex approval is not guaranteed; NPS reports sluggish Gattex sales; Eylea sales down, but expected to rebound with new indications in the second half; Ariad’s Iclusig relaunch off to a good start.

Will Velphoro’s Convenience Advantage Be Enough In Crowded ESRD Field?

With the field going generic and a new brand competitor with additional advantages on the way, Vifor Pharma is counting on lower pill burden to propel hyperphosphatemia drug Velphoro.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts